Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neutrophil cytosolic factor 2 (NCF2, p67-phox) is a regulatory and catalytic protein subunit of the multi-protein NADPH oxidase complex, predominantly expressed in phagocytes such as neutrophils. It is essential for assembling the active enzyme complex that generates reactive oxygen species (mainly superoxide) during the oxidative burst, a critical process for destroying pathogens and regulating immune cell signaling. Mutations in the NCF2 gene cause impaired ROS production leading to chronic granulomatous disease, characterized by recurrent infections and abnormal inflammation. Variations in NCF2 also contribute to autoimmunity (e.g., systemic lupus erythematosus) and are emerging as a biomarker of aggressive behavior in several cancers, including esophageal squamous cell carcinoma[1][2][3][4][6][7][8].
Modulation of NADPH oxidase activity (experiments show that mutations or protein-protein interaction inhibitors can disrupt ROS production[5][7]). Indirect inhibition or activation of immune cell ROS generation (by affecting the assembly or activity of the NADPH oxidase complex)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neutrophil cytosolic factor 2 (NCF2).